The prevention of infection-associated cancers

Carcinogenesis

Volumn 32, Issue 6, 2011, Pages 787-795

  de Flora, Silvio ^a   Bonanni, Paolo ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMOXICILLIN; ANGIOGENESIS INHIBITOR; ANTIINFECTIVE AGENT; ANTIOXIDANT; BISMUTH; CLARITHROMYCIN; DITHIOL DERIVATIVE; DITHIOLETHIONE; FURALOZIDONE; GLYCYRRHIZIC ACID; ISOTHIOCYANIC ACID; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; RIFABUTIN; SELENIUM; TETRACYCLINE; TRITERPENOID; UNCLASSIFIED DRUG; VACUOLATING TOXIN; WART VIRUS VACCINE;

CANCER CONTROL; CANCER GROWTH; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CHEMOPROPHYLAXIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE TRANSMISSION; ERADICATION THERAPY; GINSENG; HELICOBACTER INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; KAPOSI SARCOMA; NEOPLASM; NONHUMAN; PAPILLOMAVIRUS INFECTION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; VACCINATION;

EID: 79958188900     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr054     Document Type: Review

References (119)

1. Rous,P. (1911) Transmission of a malignant new growth by means of a cell-free filtrate. J Am. Med. Assoc., 56, 198.
2. Doll,R. et al. (1981) The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl Cancer Inst., 66, 1191-1308.
3. Doll,R. (1998) Epidemiological evidence of the effects of behavior and the environment on the risk of human cancer. Recent Res. Cancer Res., 154, 3-21.
4. Pisani,P. et al. (1997) Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol. Biomarkers. Prev., 6, 387-400.
5. Parkin,D.M. (2006) The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer, 118, 3030-3044.
6. zur Hausen,H. (2009) The search for infectious causes of human cancers: where and why (Lecture). Virology, 392, 1-10.
7. International Agency for Research on Cancer. (1994) IARC Monograph on the Evaluation of Carcinogenic Risks to Human. Vol. 59, International Agency for Research on Cancer, Lyon, pp.1-255.
8. International Agency for Research on Cancer. (2007) IARC Monograph on the Evaluation of Carcinogenic Risks to Humans. Vol. 90, International Agency for Research on Cancer, Lyon, pp.1-636.
9. International Agency for Research on Cancer. (2011) IARC Monograph on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Vol. 100B, Lyon, in press.
10. White,M.K. et al. (2005) Human polyomaviruses and brain tumors. Brain Res. Rev., 50, 69-85.
11. Lin,P.Y. et al. (2008) Prevalence and genotype identification of human JC virus in colon cancer in Taiwan. J. Med. Virol., 80, 1828-1834.
12. Feng,H. et al. (2008) Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science, 319, 1096-1100.
13. Carbone,M. et al. (1994) Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene, 9, 1781-1790.
14. Cerrano,P.G. et al. (2003) Simian virus 40 and malignant mesothelioma (review). Int. J. Oncol., 22, 187-194.
15. International Agency for Research on Cancer. (1997) IARC Monograph on the Evaluation of Carcinogenic Risks to Humans. Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus. Vol. 70, International Agency for Research on Cancer, Lyon, pp.1-494.
16. International Agency for Research on Cancer. (1996) IARC Monograph on the Evaluation of Carcinogenic Risks to Humans. Human immunodeficiency viruses and human T-cell lymphotropic viruses. Vol. 67, International Agency for Research on Cancer, Lyon, 1-394.
17. Schlaberg,R. et al. (2009) XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc. Natl Acad. Sci. USA, 106, 16351-16356.
18. Mager,D.L. (2006) Bacteria and cancer: cause, coincidence or cure? A review. J. Transl. Med., 4, 14.
19. International Agency for Research on Cancer. (1994) IARC Monograph on the Evaluation of Carcinogenic Risks to Humans. Schistosomes liver flukes, and Helicobacter pylori. Vol. 61, Lyon, pp.1-241.
20. Dehio,C. (2005) Bartonella-host-cell interactions and vascular tumour formation. Nat. Rev. Microbiol., 3, 621-631.
21. Blaser,M.J. (2008) Understanding microbe-induced cancers (Commentary). Cancer Prev. Res., 1, 15-20.
22. Littman,A.J. et al. (2005) Chlamydia pneumoniae and lung cancer: epidemiologic evidence. Cancer Epidemiol. Biomarkers Prev., 14, 773-778.
23. American Cancer Society. (2007) Global Cancer Facts & Figures. http://www.cancer.org/acs/groups/content/@nho/documents/document/caff200 7pwsecuredpdf.pdf.
24. Kinross,J.M. et al. (2008) The human gut microbiome: implications for future health care. Curr. Gastroenterol. Rep, 10, 396-403.
25. de Martell,C. et al. (2009) Infections and cancer: established associations and new hypotheses. Crit. Rev. Oncol. Hematol., 70, 183-194.
26. Thun,M.J. et al. (2010) The global burden of cancer: priorities for prevention. Carcinogenesis, 31, 100-110.
27. De Flora,S. et al. (2005) The epidemiological revolution of the 20th century. FASEB J., 19, 892-897.
28. Last,J.M. (1986) Scope and methods of prevention. In Last,J.M., Chin,J., Fielding,J.E., Frank,A.L., Lashoff,J.C. and Wallace,R.B. (eds.) Maxcy-Rosenau, Public Health and Preventive Medicine. Appleton-Century-Crofts, Norwalk, CT, pp. 3-7.
29. De Flora,S. et al. (2005) Overview of mechanisms of cancer chemopreventive agents. Mutat. Res., 591, 8-15.
30. Papanicolau,G.N. et al. (1941) The diagnostic value of vaginal smears in carcinoma of the uterus. Am. J. Obstet. Gynecol., 42, 193-205.
31. Cutts,F.T. et al. (2007) Human papillomavirus and HPV vaccines: a review. Bull. World Health Organ., 85, 719-726.
32. Bhatla,N. et al. (2009) The clinical utility of HPV DNA testing in cervical cancer screening strategies. Indian J. Med. Res., 130, 261-265.
33. Naucler,P. et al. (2009) Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J. Natl Cancer Inst., 101, 88-99.
34. Leung,W.K. et al. (2008) Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol., 9, 279-287.
35. Sugano,K. (2008) Gastric cancer: pathogenesis, screening, and treatment. Gastrointest. Endosc. Clin. N. Am., 18, 513-522.
36. Tan,Y.K. et al. (2006) Early diagnosis of early gastric cancer. Eur. J. Gastroenterol. Hepathol., 18, 821-829.
37. Dalton-Griffin,L. et al. (2009) Infectious causes of cancer and their detection. J. Biol., 8, 67.
38. Duncan,C.G. et al. (2009) Identification of microbial DNA in human cancer. BMC Med. Genomics, 2, 22.
39. Martellotta,F. et al. (2009) AIDS-related Kaposi's sarcoma: state of the art and therapeutic strategies. Curr. HIV Res., 7, 634-638.
40. Albini,A. et al. (2001) Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine. Cancer Res., 61, 8171-8178.
41. Ishii,Y. et al. (2010) Anti-angiogenic therapy on hepatocellular carcinoma development and progression. J. Surg. Res., 158, 69-76.
42. Blackburn,E.H. et al. (2010) Unprecedented opportunities and promise for cancer prevention research. Cancer Prev. Res., 3, 394-402.
43. Schiller,J.T. et al. (2010) Vaccines to prevent infections by oncoviruses. Annu. Rev. Microbiol., 64, 23-41.
44. Bouvard,V. et al. (2009) A review of human carcinogens - Part B: biological agents. Lancet Oncol., 10, 321-322.
45. Niller,H.H. et al. (2010) Viral. hit and run-oncogenesis: genetic and epigenetic scenarios. Cancer Lett.
46. Moore,P.S. et al. (2010) Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat. Rev. Cancer, 10, 878-889.
47. Muñoz-Fontela,C. et al. (2007) Control of virus infection by tumour suppressors. Carcinogenesis, 28, 1140-1144.
48. Mitchell,H.M. (2001) Epidemiology of infection. In Mobley,H.L.T., Mendz,G.L. and Hazel,S.L. (eds.) Helicobacter pylori: Physiology and Genetics. ASM PressWashington, DC, chapter2, pp. 7-18.
49. Chene,A. et al. (2009) Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus. Semin. Cancer Biol., 19, 411-420.
50. Kaushic,C. et al. (2011) Increased prevalence of sexually transmitted viral infections in women: the role of female sex hormones in regulating susceptibility and immune responses. J. Reprod. Immunol., 88, 204-209.
51. Kapeu,A.S. et al. (2009) Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. Am. J. Epidemiol., 169, 480-488.
52. Bagaitkar,J. et al. (2008) Tobacco use increases susceptibility to bacterial infection. Tob. Induc. Dis., 4, 12.
53. Wild,C.P. et al. (2009) A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Lett., 286, 22-28.
54. Donato,F. et al. (2002) Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am. J. Epidemiol., 155, 323-331.
55. Tsai,W.-L. et al. (2010) Viral hepatocarcinogenesis (Review). Oncogene, 29, 2309-2324.
56. De Flora,S. et al. (1985) Metabolic activation of hepatocarcinogens in chronic hepatitis B. Mutat. Res., 144, 213-219.
57. De Flora,S. et al. (1987) Metabolism of mutagens and carcinogens in woodchuck liver and its relationship with hepatitis virus infection. Cancer Res., 47, 4052-4058.
58. De Flora,S. et al. (1989) Enhanced metabolic activation of chemical hepatocarcinogens in woodchucks infected with hepatitis B virus. Carcinogenesis, 10, 1099-1106.
59. Izzotti,A. et al. (1995) Enhanced levels of DNA adducts in the liver of woodchucks infected with hepatitis virus. Chem. Biol. Interact., 97, 273-285.
60. Wakabayashi,K. et al. (1992) Food-derived mutagens and carcinogens. Cancer Res., 52, 2092s-2098s.
61. Lin,S.M. et al. (2007) Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J. Hepatol., 46, 45-52.
62. Liaw,Y.F. (2010) Does chemotherapy prevent HBV-related hepatocellular carcinoma? Pros. Dig. Liver Dis., 42 (suppl. 3), S293-S297.
63. Ikeda,K. et al. (2005) Significance of hepatitis B virus DNA clearance and early prediction of hepatocellular carcinogenesis in patients with cirrhosis undergoing interferon therapy: long-term follow up of a pilot study. J. Gastroenterol. Hepatol., 20, 95-102.
64. Yates,M.S. et al. (2007) Keap1 eye on the target: chemoprevention of liver cancer. Acta Pharmacol. Sin., 28, 1331-1342.
65. Kensler,T.W. et al. (1998) Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin-albumin adduct biomarkers. Cancer Epidemiol. Biomarkers Prev., 7, 127-134.
66. Camoirano,A. et al. (2001) Oltipraz chemoprevention trial in Qidong, People's Republic of China: results of urine genotoxicity assays as related to smoking habits. Cancer Epidemiol. Biomarkers Prev., 10, 775-783.
67. Egner,P.A. et al. (2001) Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc. Natl Acad. Sci. USA, 98, 14601-14606.
68. Kensler,T.W. et al. (2004) Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology, 127 (5 suppl. 1), S310-S318.
69. Alter,H.J. et al. (1975) The emerging pattern of post-transfusion hepatitis. Am. J. Med. Sci., 270, 329-334.
70. Kuo,G. et al. (1989) An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science, 244, 362-364.
71. Kinlin,L.M. et al. (2010) Use of gloves and reduction of risk of injury caused by needles or sharp medical devices in healthcare workers: results from a case-crossover study. Infect. Control Hosp. Epidemiol., 31, 908-917.
72. FitzSimons,D. et al. (2008) Hepatitis B virus, hepatitis C virus and other blood-borne infections in healthcare workers: guidelines for prevention and management in industrialised countries. Occup. Environ. Med., 65, 446-451.
73. Bonanni,P. (1998) Universal hepatitis B immunization: infant and infant plus adolescent immunization. Vaccine, 16, S17-S22.
74. Chang,M.H. et al. (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N. Engl. J. Med., 336, 1855-1859.
75. Plymoth,A. et al. (2009) Control of hepatocellular carcinoma through hepatitis B vaccination in areas of high endemicity: perspectives for global liver cancer prevention. Cancer Lett., 286, 15-21.
76. Chang,M.H. et al. (2009) Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J. Natl Cancer Inst., 101, 1348-1355.
77. Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma. (2010) Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J. Gastroenterol. Hepatol., 25, 657-663.
78. Takano,S. et al. (1996) Prospective assessment of donor blood screening for antibody to hepatitis C virus by first- and second-generation assays as a means of preventing posttransfusion hepatitis. Hepatology, 23, 708-712.
79. Kamal,S.M. (2008) Acute hepatitis C: a systematic review. Am. J. Gastroenterol., 103, 1283-1297.
80. Bhola,K. et al. (2007) Does avoidance of breast feeding reduce motherto-infant transmission of hepatitis C virus infection? Arch. Dis. Child., 92, 365-366.
81. Dore,G.J. et al. (2010) Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology, 138, 123-135.
82. Castello,G. et al. (2010) Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment. J. Transl. Med., 8, 109.
83. Miyake,Y. et al. (2010) Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J. Viral Hepat., 17, 287-292.
84. Elmowalid,G.A. et al. (2007) Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc. Natl Acad. Sci. USA, 104, 8427-8432.
85. Grabely,J. et al. (2009) HCV reinfection studies and the door to vaccine development. J. Hepatol., 51, 628-631.
86. Winer,R.L. et al. (2003) Genital human papillomavirus infection: incidence and risk factors in a cohort of female University students. Am. J. Epidemiol., 157, 218-226.
87. FUTURE II Study Group. (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med., 356, 1915-1927.
88. Paavonen,J. et al. (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet, 374, 301-314.
89. Olsson,S.E. et al. (2007) Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine, 25, 4931-4939.
90. Bonanni,P. et al. (2009) Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine, 27 (suppl. 1), A46-A53.
91. Guiguet,M. et al. (2009) Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol., 10, 1152-1159.
92. Dunham,S.P. (2006) Lessons from the cat: development of vaccines against lentiviruses. Vet. Immunol. Immunopathol., 112, 67-77.
93. Cafaro,A. et al. (2009) Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS. Adv. Exp. Med. Biol., 655, 189-.
94. Buchbinder,S.P. et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet, 372, 1881-1893.
95. Rerks-Ngarm,S. et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med., 361, 2209-2220.
96. Haase,A.T. (2010) Targeting early infection to prevent HIV-1 mucosal transmission. Nature, 464, 217-223.
97. Wu,X. et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science, 329, 770-773.
98. Barbaro,G. et al. (2007) HIV infection and cancer in the era of highly active antiretroviral therapy. Oncol. Rep., 17, 1121-1126.
99. Franceschi,S. et al. (2008) Kaposi sarcoma incidence in the Swiss HIV cohort study before and after highly active antiretroviral therapy. Br. J. Cancer, 99, 800-804.
100. Cáceres,W. et al. (2010) AIDS-related malignancies: revisited. P. R. Health Sci. J., 29, 70-75.
101. Pantanowitz,L. et al. (2009) Evolving spectrum and incidence of non-AIDS defining malignancies. Curr. Opin. HIV AIDS, 4, 27-34.
102. Meyskens,F.L. (2001) Development of Bowman-Birk inhibitor for chemoprevention of oral head and neck cancer. Ann. N Y Acad. Sci., 952, 116-123.
103. Piazuelo,M.B. et al. (2010) Gastric cancer: an infectious disease. Infect. Dis. Clin. North Am., 24, 853-869., vii.
104. Hu,H.M. et al. (2009) Polymorphism in COX-2 modifies the inverse association between Helicobacter pylori seropositivity and esophageal squamous cell carcinoma risk in Taiwan: a case control study. BMC Gastroenterol., 9, 37.
105. Salih,B.A. (2009) Helicobacter pylori in developing countries: the burden for how long? Saudi J. Gastroenterol., 15, 201-207.
106. Del Giudice,G. et al. (2009) Development of vaccines against Helicobacter pylori. Expert Rev. Vaccines, 8, 1037-1049.
107. Luther,J. et al. (2010) Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and metaanalysis of efficacy and tolerability. Am. J. Gastroenterol., 105, 65-73.
108. O'Connor,A. et al. (2009) Treatment of Helicobacter pylori infection. Helicobacter, 14 (suppl. 1), 46-51.
109. Gatta,L. et al. (2009) Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am. J. Gastroenterol., 104, 3081-3083.
110. Mégraud,F. (2004) H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut, 53, 1374-1384.
111. Kabir,S. (2009) Effect of Helicobacter pylori eradication on incidence of gastric cancer in human and animal models: underlying biochemical and molecular events. Helicobacter, 14, 1059-1071.
112. Fuccio,L. et al. (2009) Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk of gastric cancer? Ann. Intern. Med, 151, 121-128.
113. Wotherspoon,A.C. et al. (1993) Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet, 342, 575-577.
114. Ruggiero,P. et al. (2007) Red wine and green tea reduce H. pylori-or VacA-induced gastritis in a mouse model. World. J. Gastroenterol, 21, 349-354.
115. Zhang,L.J. et al. (2009) Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions. World J. Gastroenterol., 15, 2731-2738.
116. Futagami,S. et al. (2006) Celecoxib inhibits Cdx2 expression and prevents gastric cancer in Helicobacter pylori-infected Mongolian gerbils. Digestion, 74, 187-198.
117. Hahm,K.B. et al. (2003) Chemoprevention of Helicobacter pyloriassociated gastric carcinogenesis in a mouse model: is it possible? J. Biochem. Mol. Biol., 36, 82-94.
118. Peek,R.M. Jr et al. (2002) Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat. Rev. Cancer, 2, 28-37.
119. Izzotti,A. et al. (2007) Interplay between Helicobacter pylori and host gene polymorphisms in inducing oxidative DNA damage in the gastric mucosa. Carcinogenesis, 28, 892-898.